Zobrazeno 1 - 10
of 755
pro vyhledávání: '"Antiangiogenic agents"'
Autor:
Wenjuan Tian, Yulan Ren, Jing Lu, Chuyu Jing, Wei Zhang, Haiming Li, Tingting Wang, Zhiguo Hou, Ting Yang, Wenqing Zhu, Yi Zhang, Boer Shan, Huijuan Yang, Xi Cheng, Huaying Wang
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background The combination of anti-programmed death 1 (PD-1) inhibitors and tyrosine kinase inhibitors is an effective treatment strategy in endometrial cancer. We aimed to explore the efficacy and safety of camrelizumab plus apatinib as an
Externí odkaz:
https://doaj.org/article/add83a36851b4bfe963c2d118c5077c9
Autor:
Jian Xu, Zhihua Tang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The development of tumors and their metastasis relies heavily on the process of angiogenesis. When the volume of a tumor expands, the resulting internal hypoxic conditions trigger the body to enhance the production of various angiogenic factors. Thes
Externí odkaz:
https://doaj.org/article/6cd1daa7a7214f48960ccc59e5fb9c6c
Publikováno v:
American Heart Journal Plus, Vol 43, Iss , Pp 100406- (2024)
Externí odkaz:
https://doaj.org/article/e5154e7dbf6b44dba49bd2675fa1b0d2
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Poly (ADP-ribose) polymerase (PARP) inhibitor and antiangiogenic agent monotherapy have shown to be effective as maintenance treatment in patients with ovarian cancer (OC). However, there is currently a lack of evidence-based study to dir
Externí odkaz:
https://doaj.org/article/0e12ef5efdde4ac283bc685c1729f154
Autor:
Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Haiyan Xu, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3275-3281 (2023)
Abstract Background Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study
Externí odkaz:
https://doaj.org/article/07bdfe03836746a9bfff7fd173e5061a
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19438-19448 (2023)
Abstract Objectives The purpose of this study was to explore the efficacy and safety of toripalimab combined with anlotinib in patients with advanced non‐small cell lung cancer (NSCLC) who acquired resistance to epidermal growth factor receptor tyr
Externí odkaz:
https://doaj.org/article/8d290b90eb984770bc5c99d738ee84a5
Publikováno v:
Thoracic Cancer, Vol 14, Iss 6, Pp 535-543 (2023)
Abstract Background The combination of antiangiogenic agents with epidermal growth factor receptor inhibitors (EGFR‐TKIs) and chemotherapy with EGFR‐TKIs are the most common combination treatment options in epidermal growth factor receptor (EGFR)
Externí odkaz:
https://doaj.org/article/cc5460575a6e44588fda0ea9c982c54a
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Autor:
Lan-Lan Pang, Jia-Di Gan, Yi-Hua Huang, Jun Liao, Wei-Tao Zhuang, Wael-Abdullah-Sultan Ali, Shao-Dong Hong, Li Zhang, Wen-Feng Fang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-22 (2023)
Abstract Background & objective “Anti-angiogenetic drugs plus chemotherapy” (anti-angio-chemo) and “immune checkpoint inhibitors plus chemotherapy” (ICI-chemo) are superior to traditional chemotherapy in the first-line treatment of patients w
Externí odkaz:
https://doaj.org/article/291b408c42074ee4a2c15d48fe260a2a
Publikováno v:
Thoracic Cancer, Vol 13, Iss 18, Pp 2641-2649 (2022)
Abstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐wo
Externí odkaz:
https://doaj.org/article/f759123424b5420296231fcd9fc8edd7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.